Active Systemic Lupus Erythematosus Sle clinical trials

Explore recruiting active systemic lupus erythematosus sle clinical trials.

Recruiting active systemic lupus erythematosus sle studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Active Systemic Lupus Erythematosus Sle trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered GLPG3667 in adult subjects with active systemic lupus erythematosus.

Germany, France, Spain, Poland, Bulgaria, Hungary

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomized, double-blind, placebo-controlled extension study to assess the long-term safety and tolerability of ianalumab in patients with systemic lupus erythematosus (SIRIUS-SLE extension)

Romania, Poland, Hungary, Portugal, Italy, Slovakia +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A multicenter, randomized clinical trial comparing the efficacy and safety of certolizumab pegol and belimumab in patients with moderate or severe activity of systemic lupus erythematosus (CERT-SLE)

Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Litifilimab (BIIB059) in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care

France, Sweden, Bulgaria, Poland, Greece, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Litifilimab (BIIB059) in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care

Romania, Germany, Hungary, Netherlands, Czechia, Belgium +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1)

Italy, Germany, France, Poland, Ireland, Romania +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Active Systemic Lupus Erythematosus Sle trials by city

Active Systemic Lupus Erythematosus Sle in Toronto Active Systemic Lupus Erythematosus Sle in Vancouver Active Systemic Lupus Erythematosus Sle in Montreal Active Systemic Lupus Erythematosus Sle in Calgary Active Systemic Lupus Erythematosus Sle in Edmonton Active Systemic Lupus Erythematosus Sle in Ottawa Active Systemic Lupus Erythematosus Sle in Winnipeg Active Systemic Lupus Erythematosus Sle in Quebec City Active Systemic Lupus Erythematosus Sle in Hamilton Active Systemic Lupus Erythematosus Sle in Kitchener Active Systemic Lupus Erythematosus Sle in London Active Systemic Lupus Erythematosus Sle in Halifax Active Systemic Lupus Erythematosus Sle in New York Active Systemic Lupus Erythematosus Sle in Los Angeles Active Systemic Lupus Erythematosus Sle in Chicago Active Systemic Lupus Erythematosus Sle in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease